7.89
-0.88%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Tonghua Dongbao Pharmaceutical Co
Its shares trade on Shanghai under the ticker 600867.SS. It has been listed since 24 August 1994. In the fiscal year to 31 December 2025, it reported revenue of CN¥2.95bn and net income of CN¥1.22bn. At that date it held total assets of CN¥7.91bn and shareholders' equity of CN¥7.10bn.
Tonghua Dongbao Pharmaceutical Co., Ltd. is engaged in the manufacture, distribution, research and development of pharmaceuticals. The company is headquartered in Tonghua, Jilin. The firm provides biological products, traditional Chinese medicines and chemical supplements, applied in the treatment of diabetes and cardiovascular and cerebrovascular diseases, among others. The firm's main products portfolio consists of recombinant human insulin bulk drugs and injections, zhennaoning capsules, among others. The firm also provides medical instruments, plastic-steel windows and profiles, and operates property business. The firm distributes its products within domestic markets and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 24 Aug 1994
- Employees
- 3,054
- Website
- thdb.com ↗
Leadership
Pay as last reported
- Mr. Jiahong LiChairman of the Board, since 2019CN¥173,200
- Mr. Junyu ChiChief Accounting OfficerCN¥852,400
- Mr. Chunsheng LengGeneral Manager, Director, since 2007CN¥3.7m
- Ms. Fan SuDeputy General Manager, Secretary of the BoardCN¥992,500
- Mr. Guodong ZhangDeputy General Manager, Director, since 2018CN¥1.2m
- Mr. Wenhai ZhangDeputy General Manager, Director, since 2018CN¥1.2m
- Mr. Hong ChenDeputy General Manager, since 2007CN¥527,200
- Mr. Zhiqiang DuDeputy General ManagerCN¥1.4m
- Mr. Wei WangDirector
- Mr. Jianchun ZengDirector
- Ms. Yan BiIndependent DirectorCN¥100,000
- Ms. Dai XuIndependent DirectorCN¥100,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 43
- Environment
- 61
- Social
- 43
- Governance
- 23
- Direct emissions (scope 1)
- 16,000 t
- Energy emissions (scope 2)
- 26,000 t
- Women in the workforce
- 42.42424%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Tonghua Dongbao employs 3054 full-time staff members for its operations.
- The company manufactures recombinant human insulin bulk drugs and injections.
- Tonghua Dongbao distributes products within domestic markets and to overseas markets.
Weaknesses
- The firm operates property business alongside its core pharmaceutical activities.
- Plastic-steel windows and profiles are part of the product portfolio.
- Medical instruments are included in the firm's diverse business offerings.
Opportunities
- Traditional Chinese medicines are applied in the treatment of diabetes.
- Biological products address cardiovascular and cerebrovascular diseases among other conditions.
- Chemical supplements are provided for various therapeutic applications globally.
Threats
- The company is listed on the stock exchange since 1994.
- Headquarters are located in Tonghua, Jilin, which may limit reach.
- Regulatory changes in the Health Care sector impact pharmaceutical sales.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.